Zobrazeno 1 - 10
of 456
pro vyhledávání: '"Sara A Hurvitz"'
Autor:
Jason J Zoeller, Michael F Press, Laura M Selfors, Judy Dering, Dennis J Slamon, Sara A Hurvitz, Joan S Brugge
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gen
Externí odkaz:
https://doaj.org/article/403191507d6d430fae491ac157d03afe
Autor:
Sung-Bae Kim, Hope S Rugo, Sara A Hurvitz, Hong-Tai Chang, Chiun-Sheng Huang, Su-Hua Lee, Jung-Tung Hung, Shir-Hwa Ueng, Shin-Cheh Chen, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Richard B Schwab, James L Murray, Hsien-Kun Chang, Chwen-Cheng Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821
Externí odkaz:
https://doaj.org/article/6edfc74c39b5454884784f7a49c0a626
Autor:
Ahmad Awada, Jean-Pascal Machiels, Sylvie Rottey, Sabino De Placido, Massimo Cristofanilli, Javier Cortes, Miguel Martin, Marco Tagliamento, Marc Peeters, Mario Campone, Concetta Elisa Onesti, Hope S Rugo, Daniele Generali, Khalil Zaman, Hans Wildiers, Nadia Harbeck, Vivianne Tjan-Heijnen, Sara A Hurvitz, Guy Berchem, Rupert Bartsch, Fabio Puglisi, Volkmar Müller, Thomas Ruhstaller, PierFranco Conte
Publikováno v:
ESMO Open, Vol 5, Iss 4 (2020)
Background COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. Here we analysed measures taken in major onc
Externí odkaz:
https://doaj.org/article/7ae15fc0dc8e40fd90d140a116a2dbd1
Autor:
Kelly E McCann, Sara A Hurvitz
Publikováno v:
Drugs in Context, Vol 7, Pp 1-30 (2018)
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described. BRCA1 and BRCA2 (Breast Cancer) proteins are inv
Externí odkaz:
https://doaj.org/article/1e647c1435bf430eb16711aad2f7f56d
Publikováno v:
Drugs in Context, Vol 7, Pp 1-21 (2018)
Breast cancer is the most prevalent malignancy in women and the second most common cause of cancer-related death worldwide. Despite major innovations in early detection and advanced therapeutics, up to 30% of women with nodenegative breast cancer and
Externí odkaz:
https://doaj.org/article/ffa70641963d4c76a2965cbc79afadb4
Autor:
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients wi
Externí odkaz:
https://doaj.org/article/57d3700a66394fa696463144047acd65
Autor:
Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract These analyses explore the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib i
Externí odkaz:
https://doaj.org/article/38e11546389a453baf13464d8594cd8f
Autor:
Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b7e0ce4edf704cddba47c313492804ed
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/abb00ee86ac244e6959147aeb2f4a725
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40